Customizable bead-based platform for EV surface protein immunocapture and detection in plasma

A customizable bead-based immunocapture platform detects tumor-derived breast cancer EVs in plasma down to 1E9 EVs/ml and distinguishes HER2- and TROP2-high from low EV populations.

• Why it matters: EV liquid-biopsy profiling is limited by EV isolation challenges and by immunocapture platforms that suffer from nonspecific binding, low flexibility, and insufficient sensitivity.
• What they did: The platform uses bead-immobilized capture antibodies plus fluorescent detection antibodies, and optimization of bead conjugation chemistry to improve antibody immobilization and reduce nonspecific background.
• The result: It enables sensitive, multiplexed EV profiling directly from unprocessed plasma, supporting detection of clinically relevant differences in EV surface biomarker expression for cancer detection and monitoring.

AI summary of the abstract · may contain errors · not medical advice · read the paper.